However, direct targeting of Bcl‐XL by BH3 mimetics is associated with the induction of on‐target dose‐dependent thrombocytopenia, and thus regulators of Bcl‐XL expression might provide valuable therapeutic targets for CLL treatment [23]. Here, BCL2L1 is linked to B-cell chronic lymphocytic leukemia.